(Total Views: 595)
Posted On: 09/09/2024 1:56:39 PM
Post# of 154690
Aug. 23rd, 2024:
"We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation."
Sept. 9th, 2024:
"....we announced our selection of Syneos Health to serve as our clinical research organization (“CRO”) and implement our FDA-approved protocol to evaluate leronlimab in the treatment of patients with HIV and chronic inflammation."
" We will continue to provide updates on this trial in the coming weeks and expect to start screening patients in December 2024."
"We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation."
Sept. 9th, 2024:
"....we announced our selection of Syneos Health to serve as our clinical research organization (“CRO”) and implement our FDA-approved protocol to evaluate leronlimab in the treatment of patients with HIV and chronic inflammation."
" We will continue to provide updates on this trial in the coming weeks and expect to start screening patients in December 2024."
(2)
(0)
